Physician profile
Angelo E Canonico
NPI 1407896749
$14,542.07
in general payments reported to CMS, 2019-2025
37 companies · $19.08 in 2025
The $19.08 reported for 2025 was less than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,717 · 2020: $2,131 · 2021: $2,730 · 2022: $2,672 · 2023: $2,673 · 2024: $1,600 · 2025: $19.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,292.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $2,170.30 | 2019-2024 | Uptravi, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,121.54 | 2019-2024 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $1,642.28 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,558.20 | 2019-2024 | Trelegy Ellipta, Nucala, Arexvy |
| Insmed, INC. | $1,182.50 | 2019-2024 | Arikayce |
| Electromed, INC. | $803.60 | 2019-2024 | Smartvest |
| Grifols USA, LLC | $753.00 | 2019-2024 | Prolastin-C Liquid |
| United Therapeutics Corporation | $553.82 | 2019-2024 | Tyvaso |
| Regeneron Healthcare Solutions, INC. | $545.95 | 2019-2024 | Dupixent |
| Genzyme Corporation | $509.96 | 2020-2024 | |
| Mylan Specialty L.P. | $458.71 | 2019-2024 | Yupelri |
| Merck Sharp & Dohme LLC | $332.98 | 2019-2024 | Recarbrio, Zerbaxa, Winrevair |
| Pfizer INC. | $321.86 | 2019-2024 | |
| Amgen INC. | $290.72 | 2022-2024 | Tezspire, Tavneos |
| Genentech USA, INC. | $177.79 | 2019-2024 | Xolair |
Show all 36 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angelo Canonico listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.